These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15643002)

  • 1. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection.
    Tarragó D; Casal J; Ruiz-Contreras J; Ramos JT; Rojo P; Snippe H; Jansen WT;
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):165-70. PubMed ID: 15643002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
    Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
    Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower immunoglobulin G antibody responses to pneumococcal conjugate vaccination at the age of 2 years after previous nasopharyngeal carriage of Streptococcus pneumoniae.
    Rodenburg GD; van Gils EJ; Veenhoven RH; Bogaert D; van den Dobbelsteen GP; Berbers GA; Sanders EA
    J Pediatr; 2011 Dec; 159(6):965-70.e1. PubMed ID: 21813135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil.
    Weckx LY; Thompson A; Berezin EN; de Faria SM; da Cunha CA; Pride M; Patterson S; Gruber WC; Emini EA; Scott DA;
    Vaccine; 2012 Dec; 30(52):7566-72. PubMed ID: 23099331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.
    Kieninger DM; Kueper K; Steul K; Juergens C; Ahlers N; Baker S; Jansen KU; Devlin C; Gruber WC; Emini EA; Scott DA;
    Vaccine; 2010 Jun; 28(25):4192-203. PubMed ID: 20417262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
    Jallow S; Madhi SA; Madimabe R; Sipambo N; Violari A; Kala U; Petersen K; Naidoo S; Verwey C; Moore DP; Nunes MC
    Vaccine; 2017 Aug; 35(34):4321-4329. PubMed ID: 28688781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.
    Vernacchio L; Romero-Steiner S; Martinez JE; MacDonald K; Barnard S; Pilishvili T; Carlone GM; Ambrosino DM; Molrine DC
    J Infect Dis; 2000 Mar; 181(3):1162-6. PubMed ID: 10720547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children.
    Henckaerts I; Durant N; De Grave D; Schuerman L; Poolman J
    Vaccine; 2007 Mar; 25(13):2518-27. PubMed ID: 17034907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age.
    Vesikari T; Karvonen A; Korhonen T; Karppa T; Sadeharju K; Fanic A; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2011 Aug; 30(8):e130-41. PubMed ID: 21540760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.
    Dagan R; Givon-Lavi N; Porat N; Greenberg D
    Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Social mixing with other children during infancy enhances antibody response to a pneumococcal conjugate vaccine in early childhood.
    Salt P; Banner C; Oh S; Yu LM; Lewis S; Pan D; Griffiths D; Ferry B; Pollard A
    Clin Vaccine Immunol; 2007 May; 14(5):593-9. PubMed ID: 17344347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.
    Ekström N; Väkeväinen M; Verho J; Kilpi T; Käyhty H
    Infect Immun; 2007 Apr; 75(4):1794-800. PubMed ID: 17261612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
    Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
    Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial.
    Givon-Lavi N; Greenberg D; Dagan R
    Pediatr Infect Dis J; 2010 Aug; 29(8):756-62. PubMed ID: 20661103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.